Chemotherapy before surgery for high-risk bile duct cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether receiving chemotherapy (cisplatin, gemcitabine, and nab-paclitaxel) before surgery can improve outcomes for people with high-risk bile duct or gallbladder cancer. It compares this approach to going straight to surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 74 years old.
- You have been diagnosed with a bile duct or gallbladder cancer that can be removed by surgery.
- Your cancer has not spread to other parts of the body.
- Your cancer has certain high-risk features, such as lymph node involvement or a large tumor.
- You have not had prior surgery or chemotherapy for this cancer.
- You are in good general health (able to perform daily activities, with adequate kidney, liver, and blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of drugs given before surgery to shrink bile duct cancer and possibly improve outcomes. The drugs include an immunotherapy (tislelizumab) and three chemotherapy agents (gemcitabine, cisplatin, and S-1).
This trial tests a combination of two chemotherapy drugs and an immunotherapy drug given before surgery for bile duct cancer. The goal is to see if this approach shrinks tumors and lowers the chance of cancer coming back after surgery.
This trial tests a chemotherapy approach after surgery for bile duct or gallbladder cancers. The goal is to see if giving chemotherapy based on a detailed analysis of your tumor (called 3D-PTA) helps prevent the cancer from coming back.
This trial tests a combination of chemotherapy and immunotherapy before surgery for locally advanced bile duct cancer. The goal is to see if this approach can shrink the tumor enough to improve surgical outcomes.
This trial uses a test called MiniPDX, which grows a tiny sample of your tumor in mice to see which drugs work best. After your surgery, you'll receive chemotherapy chosen specifically for your cancer to help prevent it from coming back.
This trial tests a combination of an immunotherapy (adebrelimab), a targeted therapy (apatinib), and two chemotherapy drugs (gemcitabine and cisplatin) given before surgery for biliary tract cancers that are removable but at high risk of coming back. The goal is to see if this approach helps shrink the tumor and improve outcomes after surgery.
Hear when a new Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.